WEBULL
WebtradeDownload

MeiraGTx Holdings (MGTX) Earnings Turnaround Puts Its Valuation Back In Focus

Simply Wall St · 1d ago

MeiraGTx Holdings (MGTX) drew fresh attention after reporting second quarter and half year 2026 results, with revenue and earnings figures that marked a clear shift from prior period losses.

See our latest analysis for MeiraGTx Holdings.

The earnings swing has come alongside a sharp shift in sentiment toward MeiraGTx Holdings. The share price is at US$13.77, with a 90 day share price return of 50.82%, contributing to a 1 year total shareholder return of 72.77% and a 3 year total shareholder return of 125.37%. This suggests momentum has been building rather than fading.

If you are curious what else investors are watching in high growth areas of healthcare, it is worth scanning 40 healthcare AI stocks.

MeiraGTx Holdings has shifted from losses to profit and the stock has surged over the past year. The business story looks stronger. The key issue now is whether that recent success is already fully reflected in the price.

Price to earnings of 16.7x: Is it justified for MeiraGTx Holdings?

On a simple P/E view, MeiraGTx Holdings trades at 16.7x earnings, which sits slightly above the wider US Biotechs industry average of 16.4x, despite the strong recent share price performance.

The P/E ratio compares the current share price with earnings per share and is a common way investors frame what they are paying for each dollar of profit. For MeiraGTx Holdings, this matters because the company has only recently moved into profit and analysts currently expect earnings to decline by an average of 2.8% per year over the next 3 years while revenue is forecast to grow 6.5% per year, slower than the broader US market expectation of 13% per year.

That sets up a mixed picture. On one hand, the P/E of 16.7x is below the wider US market average of 19.2x and well below the 33.9x peer group average, which points to a lower valuation than some similar companies. On the other hand, the same P/E sits above the estimated fair P/E ratio of 13.8x, which suggests the current pricing could have room to compress toward that level if sentiment or expectations cool.

Explore the SWS fair ratio for MeiraGTx Holdings

Result: Price-to-earnings of 16.7x (OVERVALUED).

However, there are clear risks to watch, including that MeiraGTx Holdings is still a clinical stage genetic medicines company and relies on partnered programs and trial progress.

Find out about the key risks to this MeiraGTx Holdings narrative.

Next Steps

With sentiment on MeiraGTx Holdings clearly split between recent progress and ongoing risks, it makes sense to move quickly and test the numbers yourself. To see both sides of that story in one place, take a closer look at the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond MeiraGTx Holdings?

If you stop with MeiraGTx Holdings, you risk missing other compelling setups. Give yourself more options by scanning focused stock lists built from clear, consistent filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.